MCID: BRS044
MIFTS: 59

Breast Adenocarcinoma

Categories: Cancer diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Breast Adenocarcinoma

MalaCards integrated aliases for Breast Adenocarcinoma:

Name: Breast Adenocarcinoma 12 29 6 15 17 72
Mammary Adenocarcinoma 12 72
Adenocarcinoma of Breast 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3458
NCIt 50 C5214
UMLS 72 C0858252 C3669246

Summaries for Breast Adenocarcinoma

Disease Ontology : 12 A breast carcinoma that originates in the milk ducts and/or lobules (glandular tissue) of the breast.

MalaCards based summary : Breast Adenocarcinoma, also known as mammary adenocarcinoma, is related to mammary paget's disease and inflammatory breast carcinoma. An important gene associated with Breast Adenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Zoledronic Acid and Epirubicin have been mentioned in the context of this disorder. Affiliated tissues include breast, lung and bone, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Breast Adenocarcinoma

Diseases in the Breast Adenocarcinoma family:

Rare Adenocarcinoma of the Breast

Diseases related to Breast Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 307)
# Related Disease Score Top Affiliating Genes
1 mammary paget's disease 33.6 ESR1 ERBB2 EGFR
2 inflammatory breast carcinoma 33.2 ESR1 ERBB2 EGFR
3 breast medullary carcinoma 32.8 ESR1 ERBB2
4 adenocarcinoma 31.9 TP53 PIK3CA MYC KRAS H19 ERBB2
5 prostatic hypertrophy 31.2 ESR1 EGFR EGF
6 in situ carcinoma 31.2 TP53 ESR1 ERBB2 EGFR
7 breast disease 31.1 TP53 ESR1 ERBB2 EGF BAX
8 cystadenocarcinoma 31.1 TP53 PIK3CA ERBB2 AKT1
9 ductal carcinoma in situ 31.1 TP53 ESR1 ERBB2 EGFR AKT1
10 lung benign neoplasm 31.0 TP53 KRAS EGFR
11 female breast cancer 30.9 TP53 ESR1 ERBB2
12 bone cancer 30.8 TNFSF11 MMP9 ESR1 CYCS
13 breast ductal carcinoma 30.8 TP53 ESR1 ERBB2 EGFR
14 comedo carcinoma 30.7 ESR1 ERBB2
15 colorectal adenocarcinoma 30.7 TP53 KRAS EGFR
16 gastrointestinal stromal tumor 30.7 TP53 KRAS EGFR AKT1
17 glioblastoma multiforme 30.7 TP53 PIK3CA MYC ERBB2 EGFR EGF
18 squamous cell carcinoma 30.7 TP53 PIK3CA H19 ERBB2 EGFR EGF
19 lung squamous cell carcinoma 30.7 TP53 PIK3CA KRAS EGFR AKT1
20 intrahepatic cholangiocarcinoma 30.7 TP53 KRAS EGFR
21 estrogen-receptor positive breast cancer 30.6 TP53 PIK3CA ESR1 ERBB2 EGFR AKT1
22 colon adenocarcinoma 30.6 NQO1 KRAS CDKN1A CASP8 BAX
23 leukemia, acute myeloid 30.6 TP53 MYC KRAS CASP8 AKT1
24 glioblastoma 30.5 TP53 PIK3CA MYC H19 ERBB2 EGFR
25 glioma 30.3 TP53 PIK3CA MMP9 H19 ERBB2 EGFR
26 pancreatic cancer 30.1 TP53 PIK3CA KRAS H19 ERBB2 EGFR
27 cholangiocarcinoma 30.1 TP53 PIK3CA MMP9 KRAS H19 ERBB2
28 medulloblastoma 30.0 TP53 PIK3CA MYC H19 ERBB2 EGFR
29 gastric adenocarcinoma 29.9 TP53 PIK3CA MYC MMP9 KRAS H19
30 ovarian cancer 29.6 TP53 PIK3CA MYC MMP9 KRAS H19
31 lung cancer susceptibility 3 29.4 TP53 PIK3CA NQO1 MMP9 KRAS H19
32 hepatocellular carcinoma 29.4 TP53 PIK3CA NQO1 MYC MMP9 KRAS
33 breast cancer 27.8 TP53 TNFSF11 SLC22A18 RB1CC1 PIK3CA NQO1
34 breast signet ring cell adenocarcinoma 11.2
35 breast mucinous carcinoma 11.2
36 breast secretory carcinoma 11.2
37 glycogen-rich clear cell breast carcinoma 11.2
38 acinic cell breast carcinoma 11.2
39 breast apocrine carcinoma 11.2
40 oncocytic breast carcinoma 11.2
41 uterine corpus serous adenocarcinoma 11.0 TP53 PIK3CA ERBB2
42 uterine body mixed cancer 11.0 TP53 PIK3CA ERBB2
43 anal squamous cell carcinoma 11.0 TP53 PIK3CA AKT1
44 ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 11.0 TP53 PIK3CA KRAS
45 male reproductive system disease 10.9 TP53 MYC AKT1
46 breast intraductal proliferative lesion 10.9 ERBB2 EGFR
47 glassy cell carcinoma of the cervix 10.9 ESR1 ERBB2
48 thoracic benign neoplasm 10.9 TP53 ESR1 ERBB2
49 breast benign neoplasm 10.9 TP53 ESR1 ERBB2
50 barrett's adenocarcinoma 10.9 TP53 KRAS ERBB2

Graphical network of the top 20 diseases related to Breast Adenocarcinoma:



Diseases related to Breast Adenocarcinoma

Symptoms & Phenotypes for Breast Adenocarcinoma

GenomeRNAi Phenotypes related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show all 12)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.34 EGFR PIK3CA KRAS
2 Decreased viability GR00106-A-0 10.34 KRAS
3 Decreased viability GR00221-A-1 10.34 AKT1 EGFR ESR1 PIK3CA KRAS MYC
4 Decreased viability GR00221-A-2 10.34 AKT1 ESR1 PIK3CA KRAS
5 Decreased viability GR00221-A-3 10.34 AKT1 ERBB2 MYC
6 Decreased viability GR00221-A-4 10.34 AKT1 EGFR ERBB2 ESR1 PIK3CA
7 Decreased viability GR00301-A 10.34 KRAS
8 Decreased viability GR00381-A-1 10.34 KRAS
9 Decreased viability GR00402-S-2 10.34 AKT1 EGFR ERBB2 ESR1 PIK3CA KRAS
10 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.78 AKT1 BAX CASP8 CASP9 CDKN1A SLC22A18
11 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.78 AKT1 BAX CASP8 CASP9 CDKN1A SLC22A18
12 Decreased HIV-LTR-beta-galactosidase protein expression GR00224-A-1 9.46 AKT1 CYCS MMP9 RB1CC1

MGI Mouse Phenotypes related to Breast Adenocarcinoma:

46 (show all 27)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.52 AKT1 BAX CASP8 CASP9 CDKN1A CYCS
2 growth/size/body region MP:0005378 10.51 AKT1 BAX CASP8 CASP9 CDKN1A CYCS
3 cardiovascular system MP:0005385 10.47 AKT1 CASP8 CASP9 CDKN1A CYCS EGFR
4 endocrine/exocrine gland MP:0005379 10.47 AKT1 BAX CASP8 CASP9 CDKN1A CYCS
5 immune system MP:0005387 10.45 AKT1 BAX CASP8 CASP9 CDKN1A CYCS
6 homeostasis/metabolism MP:0005376 10.43 AKT1 BAX CASP8 CDKN1A EGFR ERBB2
7 behavior/neurological MP:0005386 10.41 AKT1 BAX CDKN1A CYCS ERBB2 ESR1
8 hematopoietic system MP:0005397 10.41 AKT1 BAX CASP8 CASP9 CDKN1A CYCS
9 integument MP:0010771 10.41 AKT1 CASP8 CDKN1A EGF EGFR ERBB2
10 mortality/aging MP:0010768 10.4 AKT1 BAX CASP8 CASP9 CDKN1A CYCS
11 embryo MP:0005380 10.38 AKT1 CASP8 CASP9 CDKN1A CYCS EGFR
12 muscle MP:0005369 10.32 AKT1 BAX CASP8 CDKN1A EGFR ERBB2
13 digestive/alimentary MP:0005381 10.3 CDKN1A EGF EGFR ERBB2 ESR1 KRAS
14 neoplasm MP:0002006 10.3 AKT1 BAX CASP8 CDKN1A EGFR ERBB2
15 nervous system MP:0003631 10.28 AKT1 BAX CASP8 CASP9 CDKN1A CYCS
16 craniofacial MP:0005382 10.26 CASP9 CDKN1A CYCS EGFR ERBB2 KRAS
17 adipose tissue MP:0005375 10.23 AKT1 CDKN1A EGFR ESR1 MYC NQO1
18 limbs/digits/tail MP:0005371 10.22 BAX CDKN1A EGFR ERBB2 ESR1 KRAS
19 liver/biliary system MP:0005370 10.16 AKT1 CASP8 CDKN1A EGFR ESR1 KRAS
20 normal MP:0002873 10.07 AKT1 EGF EGFR ERBB2 ESR1 KRAS
21 reproductive system MP:0005389 10.07 AKT1 BAX CDKN1A EGF EGFR ERBB2
22 no phenotypic analysis MP:0003012 10.06 CDKN1A EGFR ESR1 KRAS MYC PIK3CA
23 hearing/vestibular/ear MP:0005377 10.05 BAX CDKN1A EGFR KRAS MYC TP53
24 respiratory system MP:0005388 9.93 AKT1 BAX CASP8 CASP9 CDKN1A EGFR
25 renal/urinary system MP:0005367 9.92 BAX CASP8 CDKN1A EGFR ESR1 KRAS
26 skeleton MP:0005390 9.77 AKT1 BAX CDKN1A CYCS EGFR ERBB2
27 vision/eye MP:0005391 9.28 BAX CDKN1A EGF EGFR KRAS MMP9

Drugs & Therapeutics for Breast Adenocarcinoma

Drugs for Breast Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 130)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zoledronic Acid Approved Phase 3 118072-93-8 68740
2
Epirubicin Approved Phase 2, Phase 3 56420-45-2 41867
3
Lapatinib Approved, Investigational Phase 2, Phase 3 388082-78-8, 231277-92-2 208908 9941095
4
Capecitabine Approved, Investigational Phase 2, Phase 3 154361-50-9 60953
5
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
6
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
7
Pertuzumab Approved Phase 3 145040-37-5, 380610-27-5 2540
8
Sodium citrate Approved, Investigational Phase 3 68-04-2
9
Tamoxifen Approved Phase 3 10540-29-1 2733526
10
Letrozole Approved, Investigational Phase 3 112809-51-5 3902
11
Lidocaine Approved, Vet_approved Phase 3 137-58-6 3676
12
Trastuzumab Approved, Investigational Phase 3 180288-69-1 9903
13
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
14
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
15
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
16
Ramucirumab Approved, Investigational Phase 3 947687-13-0
17
Goserelin Approved Phase 3 65807-02-5, 1233494-97-7 47725 5311128
18
Exemestane Approved, Investigational Phase 3 107868-30-4 60198
19
Anastrozole Approved, Investigational Phase 3 120511-73-1 2187
20
Propofol Approved, Investigational, Vet_approved Phase 3 2078-54-8 4943
21
Sevoflurane Approved, Vet_approved Phase 3 28523-86-6 5206
22
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
23
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
24
Tyrosine Approved, Investigational, Nutraceutical Phase 2, Phase 3 60-18-4 6057
25
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
26
Entinostat Investigational Phase 3 209783-80-2
27
Emodepside Investigational, Vet_approved Phase 3 155030-63-0
28 Chelating Agents Phase 3
29 Anticoagulants Phase 3
30 Calcium, Dietary Phase 3
31 Protein Kinase Inhibitors Phase 2, Phase 3
32 Antibodies Phase 3
33 Immunologic Factors Phase 3
34 Antineoplastic Agents, Immunological Phase 3
35 Antibodies, Monoclonal Phase 3
36 Immunoglobulins Phase 3
37 Selective Estrogen Receptor Modulators Phase 3
38 Hormones Phase 3
39 Estrogens Phase 3
40 Citrate Phase 3
41 Steroid Synthesis Inhibitors Phase 3
42 Antineoplastic Agents, Hormonal Phase 3
43 Estrogen Receptor Modulators Phase 3
44 Hormone Antagonists Phase 3
45 Estrogen Receptor Antagonists Phase 3
46 Estrogen Antagonists Phase 3
47 Bone Density Conservation Agents Phase 3
48 Aromatase Inhibitors Phase 3
49 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
50 Analgesics Phase 3

Interventional clinical trials:

(show all 37)
# Name Status NCT ID Phase Drugs
1 Randomized Double-blind Study to Compare Two Neo-adjuvant Treatments: an Anti-aromatase vs SERM for Postmenopausal Women With ER+ Breast Adenocarcinoma: Effect on Intermediate Predictive Biological Response to Treatment. Completed NCT00949598 Phase 3 letrozole;tamoxifen citrate
2 A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer Completed NCT00869206 Phase 3 zoledronic acid
3 A Double-Blind, Placebo-Controlled, Randomized Phase III Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Patients With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer Recruiting NCT03337724 Phase 2, Phase 3 Ipatasertib;Paclitaxel;Placebo
4 A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib and Paclitaxel vs Herceptin and Paclitaxel With Sequential and Synchronous Anthracycline Recruiting NCT03085368 Phase 2, Phase 3 lapatinib/herceptin
5 A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer Recruiting NCT02488967 Phase 3 Carboplatin;Cyclophosphamide;Doxorubicin Hydrochloride;Paclitaxel
6 A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer Recruiting NCT03199885 Phase 3 Atezolizumab;Paclitaxel
7 Randomized Controlled Trial to Assess Blockade of Voltage Gated Sodium Channels During Surgery in Operable Breast Cancer Active, not recruiting NCT01916317 Phase 3 0.5% lignocaine 60mM
8 A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer Active, not recruiting NCT00703326 Phase 3 docetaxel
9 A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer Active, not recruiting NCT02115282 Phase 3 Entinostat;Exemestane;Goserelin;Goserelin Acetate
10 Regional Anesthesia and Breast Cancer Recurrence Active, not recruiting NCT00418457 Phase 3 General anesthesia and opioids;Regional analgesia and propofol
11 Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With or Without Trastuzumab as Adjuvant Treatment for Women With HER-2 Over-Expressing or Amplified Node Positive or High-Risk Node Negative Breast Cancer Active, not recruiting NCT00005970 Phase 3 Aromatase Inhibition Therapy;Cyclophosphamide;Doxorubicin Hydrochloride;Paclitaxel;Tamoxifen Citrate
12 Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial Active, not recruiting NCT00310180 Phase 3 Anastrozole;Exemestane;Letrozole;Tamoxifen Citrate
13 A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer Suspended NCT02037529 Phase 3 Eribulin Mesylate;Paclitaxel
14 Phase II Study of Cabazitaxel as 2nd Line Treatment in Patients With HER-2 Negative Metastatic Breast Cancer Previously Treated With Taxanes Completed NCT01693549 Phase 2 Cabazitaxel
15 Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory Metastatic Prostate Cancer Completed NCT00284752 Phase 2 Abraxane
16 A Phase II Randomized, Double-Blind, Study of Ipatasertib (GDC-0068), an Inhibitor to AKT, in Combination With Paclitaxel as Neoadjuvant Treatment for Patients With Early Stage Triple Negative Breast Cancer Completed NCT02301988 Phase 2 Ipatasertib;Paclitaxel;Placebo
17 Chemoradiation With Capecitabine for Palliation of Pain From Bone Metastasis Completed NCT01784393 Phase 2
18 Assessing the Cosmesis and Toxicity of Partial Breast Irradiation Using Proton Beam Irradiation Recruiting NCT01245712 Phase 2
19 T-Cell Immune Checkpoint Inhibition Plus Hypomethylation for Locally Advanced HER2-Negative Breast Cancer - A Phase 2 Neoadjuvant Window Trial of Pembrolizumab and Decitabine Followed by Standard Neoadjuvant Chemotherapy Recruiting NCT02957968 Phase 2 Doxorubicin;Cyclophosphamide;Paclitaxel;Carboplatin;Decitabine;Pembrolizumab
20 Triple-Negative First-Line Study: Neoadjuvant Trial of Nab-Paclitaxel and MPDL3280A, a PDL-1 Inhibitor in Patients With Triple Negative Breast Cancer Recruiting NCT02530489 Phase 2 Atezolizumab;Nab-paclitaxel
21 A Phase II Trial of Palbociclib in Combination With Trastuzumab and Endocrine Therapy in Patients With Previously-treated Locally Advanced or Metastatic HER2-positive Breast Cancer (PATRICIA II) Recruiting NCT02448420 Phase 2 Palbociclib;Trastuzumab;Endocrine therapy;Chemotherapy;Antibody-Drug Conjugates
22 A Pilot Study of Talazoparib as a Neoadjuvant Study in Patients With a Diagnosis of Invasive Breast Cancer and a Deleterious BRCA Mutation Active, not recruiting NCT02282345 Phase 2 Talazoparib
23 Randomized Open-Label Neo-Adjuvant Phase II Study Comparing Ixabepilone (I) Vs. Ixabepilone Plus Cetuximab (IC) in Triple Negative Breast Cancer Patients Active, not recruiting NCT01097642 Phase 2 Cetuximab;Ixabepilone
24 A Phase I-II Study of PTX-200 Plus Sequential Weekly Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide in Patients With Metastatic and Locally Advanced Breast Cancer Active, not recruiting NCT01697293 Phase 1, Phase 2 Cyclophosphamide;Doxorubicin Hydrochloride;Paclitaxel;Triciribine Phosphate
25 A Stratified, Multicenter Phase II Trial of Transdermal CR1447 (4-OH-testosterone) in Endocrine Responsive-HER2 Negative and Triple Negative-androgen Receptor Positive Metastatic or Locally Advanced Breast Cancer Active, not recruiting NCT02067741 Phase 2 CR1447
26 Phase I/II Trial of Pembrolizumab in Combination With Binimetinib in Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer Suspended NCT03106415 Phase 1, Phase 2 Binimetinib
27 Combined Modality Radioimmunotherapy For Metastatic Breast Adenocarcinoma With Two Cycles Of Escalating Dose 90Y-DOTA-peptide-m170 and Fixed, Low Dose Paclitaxel With Blood Stem Cell Support And Cyclosporin For HAMA Suppression Unknown status NCT00009763 Phase 1 cyclosporine;paclitaxel
28 A Phase I Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4, in Patients With Adenocarcinoma of the Breast Completed NCT02204046 Phase 1 BIWA 4
29 A Phase I Study of Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) (AGX) in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma Completed NCT01161186 Phase 1 nab-paclitaxel, gemcitabine, capecitabine
30 A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab With or Without Ipilimumab in Advanced Solid Tumors Recruiting NCT02453620 Phase 1 Entinostat
31 Pilot Safety and Feasibility Study of an In Vivo Sensitivity Screen Using a Direct Tumor Microinjection Technique and FDG-PET Suspended NCT03432741 Phase 1 Belinostat;Carfilzomib;Fludeoxyglucose F-18;Gemcitabine Hydrochloride;Romidepsin
32 Search for Genetic Factors Predictive of Response to Chemotherapy in Patients With or Who Has a Mammary Adenocarcinoma in Neo-adjuvant or Metastatic Setting Unknown status NCT00959556
33 Prognostic Value of Quantitative p63 Immunostaining in Adenocarcinoma of Lung, Breast, and Pancreas Unknown status NCT01942629
34 Does Aspirin Have a Protective Role Against Chemotherapeutically Induced Ototoxicity? Unknown status NCT00578760 aspirin;placebo
35 Prognostic Relevance of Perioperative Cancer Cell Dissemination and Systemic Immune Suppression in Resectable Ductal Pancreatic Adenocarcinoma Completed NCT00495924
36 A Phase II Study of Preoperative Stereotactic Ablative Body Radiotherapy (SABR) for Early-Stage Breast Cancer: Introduction of a Novel Form of Accelerated Partial Breast Radiotherapy Recruiting NCT03137693
37 Evaluation of Myocardial Changes During BReast Adenocarcinoma Therapy to Detect Cardiotoxicity Earlier With MRI - The EMBRACE MRI Study Recruiting NCT02306538

Search NIH Clinical Center for Breast Adenocarcinoma

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Thiotepa

Genetic Tests for Breast Adenocarcinoma

Genetic tests related to Breast Adenocarcinoma:

# Genetic test Affiliating Genes
1 Breast Adenocarcinoma 29

Anatomical Context for Breast Adenocarcinoma

MalaCards organs/tissues related to Breast Adenocarcinoma:

41
Breast, Lung, Bone, T Cells, Endothelial, Brain, Lymph Node

Publications for Breast Adenocarcinoma

Articles related to Breast Adenocarcinoma:

(show top 50) (show all 4426)
# Title Authors PMID Year
1
CLAPO syndrome: identification of somatic activating PIK3CA mutations and delineation of the natural history and phenotype. 71
29446767 2018
2
PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours. 71
26266975 2015
3
Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. 71
26266985 2015
4
Oculoectodermal syndrome is a mosaic RASopathy associated with KRAS alterations. 71
25808193 2015
5
Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly. 71
23100325 2013
6
De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. 71
22729223 2012
7
De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. 71
22729224 2012
8
Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. 71
22729222 2012
9
Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. 71
22658544 2012
10
A mosaic activating mutation in AKT1 associated with the Proteus syndrome. 71
21793738 2011
11
Autoimmune lymphoproliferative syndrome-like disease with somatic KRAS mutation. 71
21063026 2011
12
Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern. 71
17673550 2007
13
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. 71
17611497 2007
14
Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations. 71
17332249 2007
15
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. 71
15608678 2005
16
Mutation of the PIK3CA gene in ovarian and breast cancer. 71
15520168 2004
17
High frequency of mutations of the PIK3CA gene in human cancers. 71
15016963 2004
18
Truncating mutations of RB1CC1 in human breast cancer. 71
12068296 2002
19
Transcriptional map of 170-kb region at chromosome 11p15.5: identification and mutational analysis of the BWR1A gene reveals the presence of mutations in tumor samples. 71
9520460 1998
20
A new mutation of exon 5 of the P53 gene in breast cancer. 71
8364550 1993
21
Loss of heterozygosity on the short arm of chromosome 17 is associated with high proliferative capacity and DNA aneuploidy in primary human breast cancer. 71
1673792 1991
22
The human c-Kirsten ras gene is activated by a novel mutation in codon 13 in the breast carcinoma cell line MDA-MB231. 71
3627975 1987
23
Synthesis and cytotoxic activities of novel copper and silver complexes of 1,3-diaryltriazene-substituted sulfonamides. 38
30362387 2019
24
Synthesis, molecular modelling and biological significance of N-(4-(4-bromophenyl) thiazol-2-yl)-2-chloroacetamide derivatives as prospective antimicrobial and antiproliferative agents. 38
31384794 2019
25
4-(4-Bromophenyl)-thiazol-2-amine derivatives: synthesis, biological activity and molecular docking study with ADME profile. 38
31384808 2019
26
Combinatorial effects of radiofrequency hyperthermia and radiotherapy in the presence of magneto-plasmonic nanoparticles on MCF-7 breast cancer cells. 38
30982979 2019
27
Antibacterial and antiproliferative activities of the fresh leaf essential oil of Psidium guajava L. (Myrtaceae). 38
30462815 2019
28
Erythropoietin receptor induces a paclitaxel resistance phenotype in mammary adenocarcinoma cells. 38
31322257 2019
29
The carboxy-terminus of the formin FMNL1ɣ bundles actin to potentiate adenocarcinoma migration. 38
30977161 2019
30
Cytotoxic flavonoids from two Lonchocarpus species. 38
29656660 2019
31
Alpha mangostin loaded crosslinked silk fibroin-based nanoparticles for cancer chemotherapy. 38
31228853 2019
32
Green synthesis of selenium-N-heterocyclic carbene compounds: Evaluation of antimicrobial and anticancer potential. 38
31226469 2019
33
Deleterious synergistic effects of distress and surgery on cancer metastasis: Abolishment through an integrated perioperative immune-stimulating stress-inflammatory-reducing intervention. 38
30851377 2019
34
Anticancer Activity of Water-Soluble Olsalazine-PAMAM-Dendrimer-Salicylic Acid-Conjugates. 38
31412571 2019
35
Immunomodulatory and Antioxidant Activities of Sulfated Polysaccharides from Laminaria ochroleuca, Porphyra umbilicalis, and Gelidium corneum. 38
31250232 2019
36
Platinum(ii) complexes showing high cytotoxicity toward A2780 ovarian carcinoma cells. 38
31411239 2019
37
Interaction with Blood Proteins of a Ruthenium(II) Nitrofuryl Semicarbazone Complex: Effect on the Antitumoral Activity. 38
31394747 2019
38
Supramolecular trap for catching polyamines in cells as an anti-tumor strategy. 38
31391464 2019
39
Cytotoxicity screening of supercritical fluid extracted seaweeds and phenylpropanoids. 38
31004301 2019
40
Cloning, expression, and purification of the recombinant pro-apoptotic dominant-negative survivin T34A-C84A protein in Escherichia coli. 38
31004782 2019
41
Light-stable polypyridine silver(i) complexes of 1,3,5-triaza-7-phosphaadamantane (PTA) and 1,3,5-triaza-7-phosphaadamantane-7-sulfide (PTA[double bond, length as m-dash]S): significant antiproliferative activity of representative examples in aqueous media. 38
31237306 2019
42
ID1 Is Critical for Tumorigenesis and Regulates Chemoresistance in Glioblastoma. 38
31292163 2019
43
Primaquine and Chloroquine Fumardiamides as Promising Antiplasmodial Agents. 38
31374989 2019
44
Alterations in global DNA methylation and metabolism-related genes caused by zearalenone in MCF7 and MCF10F cells. 38
30953299 2019
45
Primaquine homodimers as potential antiplasmodial and anticancer agents. 38
31431364 2019
46
Structural and Aggregation Features of a Human κ-Casein Fragment with Antitumor and Cell-Penetrating Properties. 38
31408975 2019
47
Biocompatibility, in Vitro Antiproliferative, and in Silico EGFR/VEGFR2 Studies of Heteroleptic Metal(II) Complexes of Thiosemicarbazones and Naproxen. 38
31241919 2019
48
In Vitro Interactions of Moroccan Propolis Phytochemical's on Human Tumor Cell Lines and Anti-Inflammatory Properties. 38
31362402 2019
49
Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction. 38
31280963 2019
50
Malignant acanthosis nigricans as a paraneoplastic manifestation of metastatic breast cancer. 38
31360756 2019

Variations for Breast Adenocarcinoma

ClinVar genetic disease variations for Breast Adenocarcinoma:

6 (show all 11)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 RB1CC1 nsv1067860 deletion Pathogenic 8:53536328-53598019 8:52623768-52685459
2 RB1CC1 nsv1067861 deletion Pathogenic 8:53537321-53574220 8:52624761-52661660
3 SLC22A18 NM_002555.5(SLC22A18): c.864_865insNC_000011.10: g.2919738_2919848 insertion Pathogenic
4 KRAS NM_004985.5(KRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs112445441 12:25398281-25398281 12:25245347-25245347
5 PIK3CA NM_006218.4(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 3:178952085-178952085 3:179234297-179234297
6 PIK3CA NM_006218.4(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 3:178952085-178952085 3:179234297-179234297
7 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 17:7578479-7578479 17:7675161-7675161
8 PIK3CA NM_006218.4(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 3:178936094-178936094 3:179218306-179218306
9 PIK3CA NM_006218.4(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 3:178936091-178936091 3:179218303-179218303
10 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 17:7578479-7578479 17:7675161-7675161
11 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Uncertain significance rs121434592 14:105246551-105246551 14:104780214-104780214

Expression for Breast Adenocarcinoma

Search GEO for disease gene expression data for Breast Adenocarcinoma.

Pathways for Breast Adenocarcinoma

Pathways related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 185)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.33 TP53 PIK3CA MYC MMP9 KRAS ESR1
2
Show member pathways
14.19 TP53 TNFSF11 PIK3CA MYC MMP9 KRAS
3
Show member pathways
14.04 TP53 MYC MMP9 KRAS ERBB2 EGFR
4
Show member pathways
14.04 TP53 TNFSF11 MYC KRAS ESR1 ERBB2
5
Show member pathways
13.89 TP53 RB1CC1 MYC MMP9 KRAS ESR1
6
Show member pathways
13.86 TP53 TNFSF11 MYC KRAS ERBB2 EGFR
7
Show member pathways
13.85 PIK3CA MYC KRAS ERBB2 EGFR EGF
8
Show member pathways
13.71 TP53 PIK3CA MYC KRAS ERBB2 EGFR
9
Show member pathways
13.69 TP53 PIK3CA KRAS CYCS CASP9 CASP8
10
Show member pathways
13.62 TP53 PIK3CA KRAS ERBB2 EGFR EGF
11
Show member pathways
13.61 TP53 TNFSF11 KRAS ERBB2 EGFR EGF
12
Show member pathways
13.56 TP53 TNFSF11 PIK3CA MYC MMP9 KRAS
13
Show member pathways
13.49 TNFSF11 KRAS ERBB2 EGFR EGF CASP9
14
Show member pathways
13.42 KRAS ESR1 ERBB2 EGFR EGF CASP8
15
Show member pathways
13.41 TP53 MYC KRAS ERBB2 EGFR EGF
16
Show member pathways
13.17 PIK3CA MMP9 KRAS ESR1 EGFR AKT1
17
Show member pathways
13.15 TP53 PIK3CA MYC KRAS ERBB2 EGFR
18
Show member pathways
13.14 TP53 TNFSF11 PIK3CA KRAS EGFR CYCS
19
Show member pathways
13.14 TP53 TNFSF11 PIK3CA MMP9 KRAS EGFR
20
Show member pathways
13.14 TP53 PIK3CA MYC MMP9 KRAS EGFR
21
Show member pathways
13.06 PIK3CA KRAS ERBB2 EGFR EGF AKT1
22
Show member pathways
13.05 PIK3CA KRAS ERBB2 EGFR EGF AKT1
23
Show member pathways
13.02 PIK3CA KRAS ERBB2 EGFR CASP9 AKT1
24
Show member pathways
13.01 TP53 PIK3CA MYC KRAS CYCS CDKN1A
25 12.99 TP53 MYC KRAS ERBB2 EGFR EGF
26
Show member pathways
12.95 TP53 PIK3CA KRAS ERBB2 EGFR EGF
27
Show member pathways
12.93 TP53 MYC ESR1 CYCS CDKN1A CASP9
28
Show member pathways
12.93 TP53 PIK3CA KRAS ESR1 ERBB2 CYCS
29
Show member pathways
12.9 PIK3CA MYC KRAS CDKN1A AKT1
30
Show member pathways
12.9 TNFSF11 PIK3CA KRAS EGFR CYCS CASP9
31
Show member pathways
12.9 TP53 KRAS EGFR EGF CYCS CASP9
32
Show member pathways
12.87 PIK3CA KRAS EGFR EGF AKT1
33
Show member pathways
12.81 TP53 PIK3CA MYC KRAS ERBB2 EGFR
34
Show member pathways
12.8 TNFSF11 PIK3CA CYCS CASP9 CASP8 AKT1
35
Show member pathways
12.8 PIK3CA EGFR EGF CYCS CASP9 BAX
36
Show member pathways
12.79 TP53 PIK3CA MYC KRAS ERBB2 EGFR
37
Show member pathways
12.78 TP53 PIK3CA MMP9 KRAS ESR1 ERBB2
38 12.77 TP53 PIK3CA MYC MMP9 KRAS ERBB2
39
Show member pathways
12.72 TNFSF11 PIK3CA MYC KRAS ESR1 ERBB2
40
Show member pathways
12.71 TP53 PIK3CA KRAS ERBB2 EGFR AKT1
41
Show member pathways
12.67 TP53 PIK3CA KRAS ERBB2 EGFR CASP9
42
Show member pathways
12.64 PIK3CA MYC KRAS EGFR EGF CDKN1A
43
Show member pathways
12.64 TP53 TNFSF11 PIK3CA NQO1 MYC KRAS
44
Show member pathways
12.63 TP53 PIK3CA MYC CDKN1A CASP9 BAX
45
Show member pathways
12.62 PIK3CA KRAS EGFR EGF CASP9 AKT1
46
Show member pathways
12.61 TP53 MYC CYCS CDKN1A CASP9 CASP8
47 12.6 TP53 PIK3CA MYC KRAS CDKN1A BAX
48
Show member pathways
12.59 PIK3CA KRAS EGFR EGF AKT1
49
Show member pathways
12.58 PIK3CA KRAS ESR1 CASP9 AKT1
50
Show member pathways
12.56 PIK3CA ESR1 ERBB2 EGFR EGF AKT1

GO Terms for Breast Adenocarcinoma

Cellular components related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.97 TP53 RB1CC1 PIK3CA NQO1 KRAS ESR1
2 cytoplasm GO:0005737 9.86 TP53 TNFSF11 SLC22A18 RB1CC1 PIK3CA NQO1
3 protein-containing complex GO:0032991 9.23 TP53 MYC ESR1 EGFR CDKN1A CASP9

Biological processes related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Name GO ID Score Top Affiliating Genes
1 cell proliferation GO:0008283 9.99 TP53 MYC EGFR BAX AKT1
2 response to organic cyclic compound GO:0014070 9.97 NQO1 EGFR CDKN1A CASP9
3 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.9 CASP9 CASP8 BAX
4 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.9 PIK3CA EGFR AKT1
5 positive regulation of cell growth GO:0030307 9.9 ERBB2 EGFR AKT1
6 liver development GO:0001889 9.9 RB1CC1 PIK3CA KRAS EGFR
7 cellular response to mechanical stimulus GO:0071260 9.89 EGFR CASP8 AKT1
8 Ras protein signal transduction GO:0007265 9.89 TP53 KRAS CDKN1A
9 cellular response to drug GO:0035690 9.88 TP53 MYC EGFR
10 positive regulation of epithelial cell proliferation GO:0050679 9.88 MYC ERBB2 EGFR
11 glucose metabolic process GO:0006006 9.88 PIK3CA MYC AKT1
12 cellular response to growth factor stimulus GO:0071363 9.88 ERBB2 EGFR AKT1
13 cellular response to organic cyclic compound GO:0071407 9.88 MYC CASP9 CASP8 AKT1
14 positive regulation of smooth muscle cell proliferation GO:0048661 9.87 MYC EGFR AKT1
15 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.87 TP53 CDKN1A BAX
16 positive regulation of fibroblast proliferation GO:0048146 9.87 MYC ESR1 EGFR CDKN1A
17 positive regulation of neuron apoptotic process GO:0043525 9.86 NQO1 CASP9 BAX
18 epidermal growth factor receptor signaling pathway GO:0007173 9.86 PIK3CA EGFR EGF AKT1
19 negative regulation of Notch signaling pathway GO:0045746 9.85 EGFR EGF AKT1
20 cellular response to cadmium ion GO:0071276 9.85 MMP9 EGFR AKT1
21 cellular response to UV GO:0034644 9.85 TP53 MYC CASP9 BAX
22 positive regulation of protein phosphorylation GO:0001934 9.85 RB1CC1 MMP9 KRAS ERBB2 EGFR AKT1
23 cellular response to reactive oxygen species GO:0034614 9.84 MMP9 EGFR AKT1
24 cellular response to epidermal growth factor stimulus GO:0071364 9.84 MYC ERBB2 EGFR AKT1
25 phosphatidylinositol 3-kinase signaling GO:0014065 9.83 PIK3CA ERBB2 AKT1
26 negative regulation of fibroblast proliferation GO:0048147 9.83 TP53 MYC BAX
27 response to antibiotic GO:0046677 9.82 TP53 CASP9 CASP8
28 response to gamma radiation GO:0010332 9.82 TP53 MYC BAX
29 regulation of cell motility GO:2000145 9.81 ERBB2 EGFR EGF
30 positive regulation of DNA binding GO:0043388 9.81 MYC MMP9 EGF
31 positive regulation of release of cytochrome c from mitochondria GO:0090200 9.8 TP53 MMP9 BAX
32 positive regulation of phosphorylation GO:0042327 9.8 TNFSF11 EGFR EGF
33 positive regulation of protein kinase B signaling GO:0051897 9.8 TNFSF11 PIK3CA ESR1 ERBB2 EGFR EGF
34 ERK1 and ERK2 cascade GO:0070371 9.79 TNFSF11 MYC EGF
35 mammary gland alveolus development GO:0060749 9.76 TNFSF11 ESR1 EGF
36 negative regulation of apoptotic process GO:0043066 9.76 TP53 RB1CC1 NQO1 MYC MMP9 EGFR
37 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.72 TP53 ESR1
38 positive regulation of mitochondrial membrane potential GO:0010918 9.72 MYC AKT1
39 anoikis GO:0043276 9.72 PIK3CA AKT1
40 vagina development GO:0060068 9.71 ESR1 BAX
41 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.71 TP53 EGFR
42 ERBB2 signaling pathway GO:0038128 9.71 PIK3CA ERBB2 EGFR EGF
43 response to cobalt ion GO:0032025 9.69 CASP9 CASP8
44 signal transduction by p53 class mediator GO:0072331 9.68 TP53 CDKN1A
45 activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097296 9.68 CASP8 BAX
46 activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome c GO:0008635 9.67 CYCS CASP9 BAX
47 response to UV-A GO:0070141 9.66 EGFR AKT1
48 positive regulation of MAP kinase activity GO:0043406 9.65 TNFSF11 KRAS ERBB2 EGFR EGF
49 negative regulation of ERBB signaling pathway GO:1901185 9.63 ERBB2 EGFR EGF
50 intrinsic apoptotic signaling pathway GO:0097193 9.61 TP53 CDKN1A BAX

Molecular functions related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.85 TP53 MYC ERBB2 EGFR BAX
2 ubiquitin protein ligase binding GO:0031625 9.77 TP53 SLC22A18 EGFR CDKN1A CASP8
3 protein kinase binding GO:0019901 9.7 TP53 RB1CC1 ESR1 EGFR CDKN1A CASP9
4 protein phosphatase binding GO:0019903 9.61 TP53 ERBB2 EGFR
5 identical protein binding GO:0042802 9.61 TP53 NQO1 MMP9 ESR1 ERBB2 EGFR
6 nitric-oxide synthase regulator activity GO:0030235 9.43 ESR1 EGFR AKT1
7 cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097199 9.4 CASP9 CASP8
8 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 8.32 PIK3CA
9 protein binding GO:0005515 10.28 TP53 TNFSF11 RB1CC1 PIK3CA NQO1 MYC

Sources for Breast Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....